Fimasartan

Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals. It is grouped under the following drug class(es): Angiotensin II Receptor Blockers (ARBs). Its therapeutic use is listed as antihypertensives and cardiovascular. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include FImasartanum and Kanarb. Its PubChem CID is 9870652.

CAS No 247257-48-3
Molecular Formula C27H31N7OS
Molecular Weight 501.6 g/mol
Synonyms 2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide

Frequently Asked Questions